论文部分内容阅读
Progabide(Ⅱ),化学名为4一[[α-(4-氯苯基)-5-氟亚水杨基]氨基]丁酰胺,是一种新型GABA(γ-氨基丁酸)受体激动剂。它能透过血脑屏障,毒性较小,在动物实验中具有广谱抗癲癎活性,近年来已受到人们的广泛注意。1980年以来已有数篇临床报道。Baruzzi等在对37名严重癲癎患者进行的试验中发现,Ⅰ可使50％以上患者的症状明显改善,双盲安慰剂对照试验也进一步证明了它的疗效。但也有报道Ⅰ与安慰剂无任何区别。本文作者采用随机方法进行双盲双重交叉试验,
Progabide (II), a chemical name of 4 [[α- (4-chlorophenyl) -5-fluorosalicylalideneamino] butyramide, is a novel agonist of GABA (γ-aminobutyric acid) Agent. It can penetrate the blood-brain barrier and is less toxic. It has broad-spectrum anti-epileptic activity in animal experiments and has drawn extensive attention in recent years. There have been several clinical reports since 1980. In a trial of 37 patients with severe epilepsy, Baruzzi et al. Found that I significantly improved the symptoms in more than 50% of patients and double-blind placebo-controlled trials further demonstrate its efficacy. However, there are also reports of no difference between placebo and placebo. The authors used a double-blind, double-crossover trial using a randomized approach,